Invasive pneumococcal disease in Australia, 2003
DOI:
https://doi.org/10.33321/cdi.2004.28.48Keywords:
invasive pneumococcal disease, Streptococcus pneumoniae, surveillance, vaccinationAbstract
There were 2,174 cases of invasive pneumococcal disease (IPD) notified to the National Notifiable Diseases Surveillance System (NNDSS) in Australia in 2003; a rate of 10.9 per 100,000 population. The notification rate varied between states and territories and by geographical region with the highest rates in the north of the country. Invasive pneumococcal disease was reported most frequently in children aged less than two years (98.8 cases per 100,000 population). Enhanced surveillance for IPD in 2003 was carried out in all states and territories, providing additional data on 1,842 (85%) of all notified cases. Rates of IPD in Indigenous Australians were three times the rate in non-Indigenous Australians. There were 125 deaths attributed to IPD resulting in an overall case fatality rate of 6.8 per cent. Seventy-one per cent of all pneumococcal isolates serotyped were serotypes in the seven-valent conjugate vaccine and 91 per cent were serotypes in the 23-valent polysaccharide pneumococcal vaccine. The clinical presentation and risk factors for IPD varied between Indigenous and non-Indigenous cases and non-vaccine serotypes occurred more frequently among Indigenous children and adults. Data from three years of surveillance indicate an early impact of the 7-valent vaccine in the target population. Commun Dis Intell 2004;28:441–454.
Downloads
References
Collignon PJ, Turnbridge JD. Antibiotic resistance in Streptococcus pneumoniae. Med J Aust 2000;173:S58–S64.
Turnidge JD, Bell JM, Collignon PJ. Rapidly emerging antimicrobial resistances in Streptococcus pneumoniae in Australia. Med J Aust 1999;170:152–155.
Craig AS, Erwin PC, Schaffner W, Elliott JA, Moore WL, Ussery XT, et al. Carriage of multidrug resistant Streptococcus pneumoniae and impact of chemoprophylaxis during an outbreak of meningitis at a day care centre. Clin Infect Dis 1999;29:1257–1264.
Nimmo GR, Bell JM, Collignon PJ. Fifteen years of surveillance by the Australian Group for Antimicrobial Resistance (AGAR). Comm Dis Intell 2003;27 Supplement:S47–S54.
Douglas RM, Miles HB. Vaccination against Streptococcus pneumoniae in childhood:lack of demonstrable benefit in young Australian children. J Infect Dis 1984;149:861–869.
Black S, Shinefield H, Fireman B, Lewis E, Ray P, Hansen JR. Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Pediatr Infect Dis J 2000;19:187–195.
Roche P, Krause V. Invasive pneumococcal disease in Australia, 2001. Commun Dis Intell 2002;26:505–519.
Roche P, Krause V, Andrews R, Carter L, Coleman D, Cook H, et al. Invasive pneumococcal disease in Australia, 2002. Comm Dis Intell 2003;27:466–477.
National Health and Medical Research. The Australian Immunisation Handbook. 8th edition. Canberra:NH&MRC;2003.
Whitney CG, Farley MM, Hadler J, Harrison LH, Bennett NM, Lynfield R, et al. Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. N Engl J Med 2003;348:1737–1746.
Dear K, Holden J, Andrews R, Tatham D. Vaccines for preventing pneumococcal infections in adults. The Cochrane Library 2004;2.
Kelly H, Attia J, Andrews R, Heller RF. The number needed to vaccinate (NNV) and population estimates of the NNV:comparison of influenza and pneumococcal vaccine programmes for people aged 65 years and over. Vaccine 2004;22:2192–2198.
Robinson P. Meningococcal disease and the law:does non-notification really happen? Commun Dis Intell 1999;23:97–101.
Gjini A, Stuart JM, George RC, Nichols T, Heyderman RS. Capture-recpature analysis and pneumococcal meningitis estimates in England. Emerg Infec Dis 2004;10:87–93.
Downloads
Published
How to Cite
License
Copyright (c) 2004 Communicable Diseases Intelligence
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
